OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment. (Optimise)

AstraZeneca

Status: Completed

Conditions: Diabetes

Study type: Observational

Funder types: Industry

Identifiers

NCT00681850

D3560L00071

Details and patient eligibility

About

Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.

Enrollment: 4,027 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of informed Consent
• Patients suffering from diabetes type II, insulin dependent or not insulin dependent.

Exclusion criteria

• Type I diabetes
• Pregnancy diabetes
• Hospitalisation, as this is a primary care study
• Patients who are member of the Belgian Diabetes Convention

Trial design

4,027 participants in 2 patient groups

1

Description:

Control group

2

Description:

Benchmarking group